Rigel Pharmaceuticals, Inc. Appoints Alison L. Hannah, M.D. to Its Board of Directors
May 14, 2021 at 07:30 am EDT
Rigel Pharmaceuticals, Inc. announced that it has appointed Alison L. Hannah, M.D. to its Board of Directors. Dr. Hannah brings over three decades of pharmaceutical industry experience to Rigel, including a deep knowledge of clinical development strategy in hematology and oncology with a focus on molecularly targeted therapies. Alison L. Hannah, M.D. currently serves as Chief Medical Officer for CytomX Therapeutics. Prior to joining CytomX, Dr. Hannah served as a consultant to nearly 30 pharmaceutical and biotechnology companies directing the development of investigational cancer therapies.